Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Schlaak, Max
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)	Active, not recruiting	3	407	Europe, US, RoW	IO102-IO103, Pembrolizumab	IO Biotech, Syneos Health, Merck Sharp & Dohme LLC	Metastatic Melanoma, Unresectable Melanoma	07/25	09/27
PRISM-MEL-301, NCT06112314: IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma	Recruiting	3	680	Europe, US, RoW	Brenetafusp, IMC-F106C, Nivolumab, OPDIVO, Nivolumab + Relatlimab, OPDUALAG	Immunocore Ltd	Advanced Melanoma	10/27	10/27
DEBOVES, Orlane
PRISM-MEL-301, NCT06112314: IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma	Recruiting	3	680	Europe, US, RoW	Brenetafusp, IMC-F106C, Nivolumab, OPDIVO, Nivolumab + Relatlimab, OPDUALAG	Immunocore Ltd	Advanced Melanoma	10/27	10/27
RECAST DLE, NCT05591222 / 2022-000831-21: Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus	Active, not recruiting	2	72	Europe, Canada, US, RoW	Placebo/Daxdilimab, Daxdilimab, HZN-7734	Amgen, Horizon Therapeutics Ireland DAC	Discoid Lupus Erythematosus	09/25	09/25
Bauriedl, Jessica
PRISM-MEL-301, NCT06112314: IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma	Recruiting	3	680	Europe, US, RoW	Brenetafusp, IMC-F106C, Nivolumab, OPDIVO, Nivolumab + Relatlimab, OPDUALAG	Immunocore Ltd	Advanced Melanoma	10/27	10/27